Albert Einstein Cancer Center

Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure

Event-free survival following all-trans-retinoic acid (ATRA) -based therapy for acute promyelocytic leukemia (APL) averages 70% at 5 years. While arsenic trioxide (ATO) can induce remissions in 95% of relapsed patients, few studies have addressed the integration of ATO into the primary management of APL. This collaborative study, which included AECC investigator R.E. Gallagher, examined the efficacy of a single cycle of ATO-based consolidation therapy in a treatment regimen designed to decrease exposure to other cytotoxic agents. After induction with ATRA and daunorubicin (DRN), untreated patients with APL received 3 days of cytarabine and DRN followed by 30 doses of ATO beginning on day 8. Molecular remitters received 2 years of risk-based maintenance therapy. Forty-one of 45 patients receiving induction therapy achieved remission; four patients died (one before treatment was initiated). Thirty-seven patients received consolidation and maintenance. With a median follow-up of 2.7 years, estimated disease-free survival was 90%; overall survival for all patients was 88%. These data, combined with other recent studies using ATO in the primary management of APL, demonstrate the important role that ATO can play in the primary management of this curable disease. The authors conclude that future studies should focus on reducing the toxicity of treatment without increasing the relapse rate. 

Click here to log in